{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:53Z","timestamp":1793771993981,"version":"4.6.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026925","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T17:54:17Z","timestamp":1730483657000},"page":"2788-2792","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in\u00a0AML"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0974-9897","authenticated-orcid":false,"given":"Vishvaas I.","family":"Ravikumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"additional","affiliation":[{"name":"2Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"3Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"},{"name":"4Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"O\u2019Nions","sequence":"additional","affiliation":[{"name":"5Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-0994","authenticated-orcid":false,"given":"Daniel T.","family":"Peters","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer N.","family":"Saultz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"2Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"},{"name":"3Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2024122616205006200_bib1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"21","key":"2024122616205006200_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2024122616205006200_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2024122616205006200_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"13","key":"2024122616205006200_bib5","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024122616205006200_bib6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2024122616205006200_bib7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2024122616205006200_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2024122616205006200_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient\u00a0samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"issue":"12","key":"2024122616205006200_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024122616205006200_bib11","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024122616205006200_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data\u00a0from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"issue":"20","key":"2024122616205006200_bib13","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2024122616205006200_bib14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024122616205006200_bib15","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"20","key":"2024122616205006200_bib16","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"2024122616205006200_bib17","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/26\/2788\/2349182\/blood_bld-2024-026925r1-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/26\/2788\/2349182\/blood_bld-2024-026925r1-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:21:03Z","timestamp":1735212063000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/26\/2788\/525851\/Refined-ELN-2024-risk-stratification-improves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":17,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026925","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}